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Abstract
The Cytotoxic Necrotizing Factor 1 (CNF1) is a protein toxin which is a major virulence factor of pathogenic Escherichia coli
strains. Here, we identified the Lutheran (Lu) adhesion glycoprotein/basal cell adhesion molecule (BCAM) as cellular receptor
for CNF1 by co-precipitation of cell surface molecules with tagged toxin. The CNF1-Lu/BCAM interaction was verified by
direct protein-protein interaction analysis and competition studies. These studies revealed amino acids 720 to 1014 of CNF1
as the binding site for Lu/BCAM. We suggest two cell interaction sites in CNF1: first the N-terminus, which binds to p37LRP
as postulated before. Binding of CNF1 to p37LRP seems to be crucial for the toxin’s action. However, it is not sufficient for
the binding of CNF1 to the cell surface. A region directly adjacent to the catalytic domain is a high affinity interaction site for
Lu/BCAM. We found Lu/BCAM to be essential for the binding of CNF1 to cells. Cells deficient in Lu/BCAM but expressing
p37LRP could not bind labeled CNF1. Therefore, we conclude that LRP and Lu/BCAM are both required for toxin action but
with different functions.
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Introduction
Urinary tract infections (UTIs) are among the most common
bacterial infections of humans. More than 80% of UTIs are caused
by Uropathogenic Escherichia coli (UPEC) strains [1]. Many
pathogenic Escherichia coli strains including UPEC and strains
inducing meningitis or soft tissue infections produce Cytotoxic
Necrotizing Factor 1 (CNF1), a protein toxin which contributes to
virulence [2]. Of major importance for its role as a virulence factor
is the effect of CNF1 on epithelial barrier- and immune cell
functions [3]. Both features are controlled by Rho GTPases, which
are directly targeted by the toxin. CNF1 deamidates a specific
glutamine (Gln63/61) of Rho proteins, which is crucial for GTP
hydrolysis and therefore, the Rho proteins are arrested in a
constitutively activated state [4,5]. Rho family GTPases are
regulated in a GTPase cycle by the following cellular proteins:
GEFs (guanine nucleotide exchange factors) activate Rho proteins by
GDP/GTP-exchange, GAPs (GTPase-activating proteins) stimulate
the intrinsic GTP hydrolysis, thereby accelerating inactivation.
GDIs (guanine nucleotide dissociation inhibitors) predominantly bind the
inactive form of Rho GTPases blocking nucleotide exchange [6].
Active Rho proteins interact with several effectors, which govern a
variety of cellular processes including organization of the actin
cytoskeleton. Consequently, cells treated with CNF1 show a strong
network of actin stress fibers, filopodia and membrane ruffles [7].
CNF1 belongs to a family of single chain AB-toxins with an N-
terminal domain important for membrane translocation and the
C-terminal catalytic domain encompassing deamidase activity.
The toxin is taken up into mammalian cells by receptor-mediated
endocytosis. It has been shown that the cytosolic precursor protein
(37LRP) of the non-integrin laminin receptor (67LR) interacts with
the N-terminus (aa 1–342) of CNF1 in a yeast-two-hybrid-screen [8].
Processing of 37LRP to the mature, membrane localized 67LR is
still unclear but may originate from homo- or hetero-dimerization
of 37LRP with another 37LRP molecule or with galectin3 [9].
Moreover, it has been suggested by knockdown of 37LRP that
67LR mediates the uptake of CNF1 into cells [8].
Here, we identified the Lutheran (Lu) adhesion glycoprotein/
basal cell adhesion molecule (BCAM) as a cellular receptor for
CNF1 and show that it is essential for the intoxication of cells. The
transmembrane adhesion molecule Lu/BCAM is a member of the
immunoglobulin (Ig) superfamily with five Ig-like domains on the
extracellular site, a single transmembrane domain and a short, C-
terminal cytoplasmic tail. This protein, like 67LR is a receptor for
the extracellular matrix protein laminin. Two transcript variants,
encoding different isoforms, have been found for this gene called
Lu and BCAM. The difference between Lu and BCAM is the
length of the cytoplasmic tail (59 amino acids in Lu and 19 amino
acids in BCAM), which is thought to mediate intracellular
signaling because it contains an SH3 binding motif and 5
phosphorylation sites [10]. Lu/BCAM binds to laminin a5, which
is the major laminin a-chain in the basement membrane [11]. In
humans, Lu plays a role in vaso-occlusion of red blood cells (RBCs)
in sickle cell patients. In sickle cell RBCs, epinephrine increases a
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Lu/BCAM-mediated adhesion of the cells to laminin a5 in a
cAMP and protein kinase A-dependent manner [12]. However,
Lu/BCAM is also expressed in many other cells and tissues with a
strong appearance in epithelial and endothelial cells (for review see
[13,14]). We show that CNF1 binds to Lu/BCAM on mammalian
cells and that this interaction is crucial for the uptake of the toxin.
The interaction of CNF1 with Lu/BCAM occurs within a region
located in close proximity to the C-terminal catalytic domain,
whereas the N-terminus of CNF1 interacts with the 37LRP
precursor of the non-integrin laminin receptor [8]. Therefore,
CNF1 seems to contact two different laminin binding proteins,
using separate domains.
Results
Identification of Lu/BCAM as receptor for CNF1
Identification of the cellular receptor is a crucial task in
understanding bacterial toxins. For CNF1 it has been reported
that the N-terminal 342 amino acids of the toxin interact with the
37 kDa laminin receptor precursor (37LRP) [8]. This intracellular
protein matures to the 67 kDa cell surface-localized laminin
receptor (67LR). We confirmed a week interaction of CNF1 with
67LR by overlay assays (not shown). Therefore, we used purified
67LR from cells, which secrete this receptor into the culture
medium [15]. However, some cell lines like RBL (rat basophil
leukemia) or HeLaS3 (human cervix carcinoma, subclone 3) cells
express 37LRP but are not intoxicated by CNF1, suggesting that
another structure on the cell surface may be necessary for efficient
binding and endocytosis of the toxin. In line with this, it has been
shown, using monoclonal antibodies, that besides the N-terminal
receptor binding domain, a second part of CNF1 is involved in
binding to mammalian cells [16].
We screened for cell surface protein receptors CNF1 binds to by
incubating HeLa cells with a double-tagged GST-CNF1-GST
fusion protein at 4uC. As controls we used GST alone or the
analogue double-tagged form of the CNF family member CNFY
(GST-CNFY-GST, Yersinia pseudotuberculosis toxin CNFY). This
toxin is known to interact with a different, yet unknown receptor
on mammalian cells [17]. Following binding, we lysed the cells and
precipitated the toxin together with associated molecules, using
anti-GST magnetic beads. Eluates were separated on SDS-PAGE
and the eluted proteins were subsequently identified by nanoLC-
MS/MS. The only hit unique to the CNF1-precipitate was the
Lutheran (Lu) adhesion glycoprotein/basal cell adhesion molecule
(BCAM) (Fig. S1). This surface protein has a large extracellular Ig-
like structure and is widely expressed. Interestingly, Lu/BCAM
like the proposed CNF1 receptor 67LR interacts with laminin,
suggesting that the receptor-binding domain of CNF1 could
interact with both laminin binding structures on the cell surface.
To verify the CNF1-Lu/BCAM interaction, we repeated the
precipitation assay with HEK293 (Fig. 1A) and HeLa cells (Fig. 1B)
and analyzed the presence of Lu/BCAM in the precipitate by
Western-blotting with a specific antibody against Lu/BCAM. As
shown in Fig. 1, Lu/BCAM was exclusively co-precipitated with
GST-CNF1-GST but not with GST-CNFY-GST or GST alone.
Notably, we could not detect 37LRP/67LR in any lane by
Western-blotting although the protein was expressed in HeLa and
in HEK293 (human embryonic kidney) cells (Fig. S2).
We asked whether Lu/BCAM is an alternative receptor in the
absence of 67LR or whether binding to Lu/BCAM is generally
crucial for toxin uptake. In the latter case, blocking the interaction
of CNF1 with Lu/BCAM should inhibit the uptake of the toxin
into cells. Uptake of CNF1 can be monitored by the shift of
deamidated RhoA to higher molecular weight in SDS-PAGE [5]
and by the morphological changes of cells induced by the toxin.
To this end, we performed competition experiments with
recombinant BCAM (rBCAM) and CNF1 on HeLa cells. We
incubated the toxin with rBCAM (in a molar ratio CNF1:rBCAM
of 1:1, 1:10 and 1:100, respectively) for 20 min and then treated
cells with the mixture. As shown in Fig. 2A, preincubation of CNF
with rBCAM inhibited uptake of the toxin in a concentration-
dependent manner, indicating direct interaction of the proteins. In
a second approach, we blocked the binding of CNF1 to Lu/
BCAM directly on the cell surface. For these experiments, HeLa
cells were treated with an anti Lu/BCAM antibody (AB B12) that
binds to the extracellular domain of Lu/BCAM. As control we
used an anti-Lu/BCAM antibody (AB C16) directed against the
intracellular part of the glycoprotein. Toxin uptake was deter-
mined by the amount of modified RhoA (shift in SDS-PAGE) after
2 h of incubation. Fig. 2B shows that pre-incubation of cells with
the antibody against Lu/BCAM extracellular domain inhibited
the uptake of CNF1, whereas the control antibody had no effect.
As expected, the antibodies added to the cells without the toxin
had no effect. The data indicate that binding of CNF1 to Lu/
BCAM is required for the uptake of the toxin into cells.
Colocalization of Lu/BCAM with CNF1 but not with CNFY
To visualize CNF1 on the cell surface, we fluorescently labeled
GST-CNF1 (green) and studied colocalization with Lu/BCAM
using an antibody against the receptor and a second rhodamine
labeled antibody (red). As negative control we used labeled GST-
CNFY. Binding of the toxins was performed at 4uC and the cells
incubated for further 30 min at 37uC to allow endocytosis. The
cells were fixed and stained for Lu/BCAM. As shown in Fig. 2C
CNF1 colocalized with Lu/BCAM, whereas there was no
colocalization of CNFY with this receptor. Colocalization
occurred in vesicular structures. It is known that CNF1 is released
from endosomes following acidification [17]. Therefore, we
confirmed the colocalization of CNF1 with the endosomal marker
EEA1, which exclusively localizes to early endosomes. For
immunofluorescence we used an antibody against EEA1 and a
Author Summary
We study a crucial virulence factor produced by patho-
genic Escherichia coli strains, the Cytotoxic Necrotizing
Factor 1 (CNF1). More than 80% of urinary tract infections
(UTIs), which are counted among the most common
bacterial infections of humans, are caused by Uropatho-
genic Escherichia coli (UPEC) strains. We and others
elucidated the molecular mechanism of the E. coli toxin
CNF1. It constitutively activates Rho GTPases by a direct
covalent modification. The toxin enters mammalian cells
by receptor-mediated endocytosis. Here, we identified the
protein receptor for CNF1 by co-precipitation of cell
surface molecules with the tagged toxin and subsequent
Maldi-TOF analysis. We identified the Lutheran (Lu)
adhesion glycoprotein/basal cell adhesion molecule
(BCAM) as receptor for CNF1 and located its interaction
site to the C-terminal part of the toxin. We performed
direct protein-protein interaction analysis and competition
studies. Moreover, cells deficient in Lu/BCAM could not
bind labeled CNF1. The identification of a toxin’s cellular
receptor and receptor binding region is an important task
for understanding the pathogenic function of the toxin
and, moreover, to make the toxin accessible for its use as a
cellbiological and pharmacological tool, for example for
the generation of immunotoxins.
Identification of CNF1 Receptor
PLOS Pathogens | www.plospathogens.org 2 January 2014 | Volume 10 | Issue 1 | e1003884
second rhodamine labeled antibody (red). As shown in Fig. 2C
(top) the toxin was localized to early endosomes.
Lu/BCAM is crucial for binding and uptake of CNF1
To corroborate the requirement of Lu/BCAM for toxin binding
and/or uptake we made use of human immortalized myelogenous
leukemia cells (K562), which do not express Lu/BCAM. As
control the same cell line stably expressing recombinant Lu/
BCAM (K562-Lu/BCAM) was employed [18]. We verified
expression of Lu/BCAM and analyzed the presence of 37LRP
in the two cell-lines by Western-blotting. Whereas 37LRP is
expressed in both cell lines, Lu/BCAM could only be detected in
K562-Lu/BCAM but not in K562 cells (Fig. S2). To study the
uptake of CNF1, leukemia cells and Lu/BCAM-expressing cells
were treated with the toxin for different time periods and,
subsequently, the uptake of CNF was analyzed by the shift of
modified RhoA. The CNF1-induced shift of RhoA was incomplete
in K562 cells not expressing Lu/BCAM even after overnight
intoxication (Fig. 3A, bottom). By contrast, in Lu/BCAM
expressing cells deamidation of RhoA occurred within 1 h
(Fig. 3A, top). Apparently a low amount of toxin was taken up
into the leukemia cells which do not express Lu/BCAM. This may
occur by unspecific pinocytosis or by binding to the 67LR present
on both cell lines. The data indicate that Lu/BCAM is essential for
efficient uptake of CNF1. To further support this finding we
performed competition experiments with rBCAM and CNF1 on
K562-Lu/BCAM cells. We pre-incubated the toxin with rBCAM
(in a molar ratio CNF1:rBCAM of 1:1, 1:10 and 1:100,
respectively) for 20 min and treated the cells with the mixture.
As expected, preincubation of CNF with rBCAM inhibited uptake
of the toxin in a concentration-dependent manner (Fig. 3B).
We intended to distinguish between binding and uptake of the
toxin. Therefore, we performed fluorescence activated cell sorting
(FACS) analysis with DyLight488-labeled GST-CNF1. First, we
added increasing amounts of labeled toxin to HeLa cells,
incubated the cells for 15 min on ice and washed them with
PBS. Afterwards we analyzed the fluorescence of the cells by
FACS measurements. As expected, increasing concentrations of
the labeled toxin shifted the cells to higher fluorescence, indicating
specific binding of GST-CNF to the cells (Fig. S3, left). Data from
3 independent experiments were quantified (Fig. S3, right).
We further studied the toxin Lu/BCAM interaction and
performed competition experiments firstly with recombinant
BCAM and in a second approach with antibodies. We either
used increasing amounts of an anti-Lu/BCAM antibody directed
against the extracellular domain of the receptor or an antibody
directed against 37LRP. All competitors were used in increasing
amounts (molar ratio CNF1:competitor from 1:0 to 1:50,
respectively as indicated). The fluorescence decreased to lower
levels in the presence of the competitors rBCAM (Fig. 4A) and
anti-Lu/BCAM (Fig. 4B), respectively but not in the presence of a
50-fold molar excess of anti-37LRP (Fig. 4C). Whereas GST-
CNF1 binding was decreased with recombinant BCAM to about
25% of control, the effect was less pronounced but significant
with the antibody directed against Lu/BCAM. No change in
fluorescence was detected in the presence of the antibody against
37LRP. The data indicate that the toxin specifically binds to Lu/
BCAM.
Figure 1. Lu/BCAM is co-precipitated with CNF1 but not with CNFY. HEK293 (A) or HeLa (B) cells were incubated with GST, GST-CNF1-GST or
GST-CNFY-GST as indicated for 20 min at 4uC. Cells were harvested and lysed and the GST proteins together with their bound interaction partners
were pulled with anti-GST magnetic beads. Proteins were separated by SDS-PAGE and co-precipitated Lu/BCAM detected by Western-blotting. Note
that the major band for Lu/BCAM in the lysate runs at about 67-kDa. The glycosylated, surface exposed protein runs at higher molecular weight.
Shown is an example of at least 3 independent experiments.
doi:10.1371/journal.ppat.1003884.g001
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To verify binding of the toxin to Lu/BCAM, we performed
FACS analysis with K562 cells (Fig. 4D) and with receptor
expressing K562-Lu/BCAM cells (Fig. 4E). At first cells were
incubated with DyLight488-labeled GST-CNF1 (2 mg/mL),
washed and analyzed. In line with our precipitation experiments,
K562 cells only marginally shifted to higher fluorescence, whereas
the K562-Lu/BCAM cells showed a broad spectrum of fluorescent
cells ranging from low to high fluorescence. The latter may
Figure 2. Competition and colocalization studies with HeLa cells. GST-CNF1 was incubated with buffer or with recombinant BCAM in a molar
ratio CNF1:rBCAM of 1:1, 1:10 and 1:100, respectively for 20 min. The mixture was added to HeLa cells. Following 2 h incubation the cells were lysed
and the CNF1-catalysed deamidation of RhoA was analyzed by the shift of the modified GTPase in SDS-PAGE by Western-blotting (A). HeLa cells were
incubated with an anti Lu/BCAM antibody (AB B12) that binds to the extracellular domain or as control with an anti-Lu/BCAM antibody (AB C16)
directed against the intracellular part of the glycoprotein. GST-CNF1 was then added to the cells for 2 h. We followed the toxins uptake by the
amount of modified RhoA (shift in SDS-PAGE, B). Shown is a typical result of 3 independent experiments. Colocalization of DyLight488-labeled GST-
CNF1 with Lu/BCAM and EEA1 (C) Top: HeLa-cells were treated on ice with DyLight488-labeled GST-CNF1 (5 mg/ml) (green) for 30 min to allow
receptor binding. After 30 min cells were transferred to 37u for 30 min to induce uptake. Subsequently cells were fixed and stained for EEA1 (red) by
immunofluorescence. Images are from the middle of the confocal stack. The image on the right is a maximal projection of all confocal planes. Scale
bar indicates 10 mm. Middle: HeLa-cells were treated with labeled GST-CNF1 as in A. After fixation cells were stained for Lu/BCAM (red) by
immunofluorescence. Images are from the middle of the confocal stack. The image on the right is a magnification of the white box. Scale bar
indicates 10 mm. Bottom: HeLa-cells were treated as in A, but instead of GST-CNF1, cells were treated with DyLight488-labeled GST-CNFY (5 mg/ml)
(green). After fixation cells were stained for Lu/BCAM (red) by immunofluorescence. Images are from the middle of the confocal stack. The image on
the right is a magnification of the white box. Scale bar indicates 10 mm. Shown is a typical staining of 9 HeLa cells analyzed.
doi:10.1371/journal.ppat.1003884.g002
Figure 3. Cells not expressing Lu/BCAM do not respond to CNF1. A) K562 leukemia cells, which do not express Lu/BCAM (top) and the
isogenic cell line K562-Lu/BCAM expressing the receptor (bottom), were treated with GST-CNF1 for different time periods from 1 h to overnight (ON)
as indicated. Uptake of the toxin was analyzed by the shift of modified RhoA in SDS-PAGE. B) GST-CNF1 was incubated with buffer or with
recombinant BCAM in a molar ratio CNF1:rBCAM of 1:1, 1:10 and 1:100, respectively for 20 min. The mixture was added to K562-Lu/BCAM cells for 2 h.
Cells were lysed and the deamidation of RhoA was analyzed by the shift of the modified GTPase in SDS-PAGE by Western-blotting. Data are
representative for at least 3 independent experiments.
doi:10.1371/journal.ppat.1003884.g003
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correspond to the degree of Lu/BCAM overexpression in these
cells, which seems to vary from cell to cell. Pre-incubation of
labeled GST-CNF1 with rBCAM concordantly reduced the
amount of toxin bound to these cells but did not completely block
CNF-binding. This effect may be based on the high amount of
Lu/BCAM expressed.
Role of Lu/BCAM glycosylation
Lu/BCAM is known to be modified by glycosylation. Four N-
glycosylation sites have been identified, which account for
approximately 15% weight composition of the protein [13]. Some
bacterial toxins are recruited to cellular membranes by binding to
sugar chains before a high affinity interaction with a surface
protein occurs. This has been shown for example for tetanus
neurotoxin [19]. In our co-precipitation assay (Fig. 1) only the high
molecular weight form of Lu/BCAM was enriched by binding to
CNF1, whereas the lower molecular weight form was not
precipitated with CNF, although it appeared as the most
prominent band in the lysate. This indicates that N-glycosylation
may be important for interaction with the toxin. Therefore, we
tested, whether N-glycosylation of Lu/BCAM plays a role for
CNF1 binding. The recombinant BCAM used in this study was
purified from Lu/BCAM-overexpressing mammalian cells. The
protein is fully glycosylated. We treated recombinant BCAM with
PNGaseF and analyzed deglycosylation by SDS-PAGE. Deglyco-
sylated rBCAM should run lower according to its lower molecular
weight. As shown in Fig. S4A, PNGaseF-treated rBCAM runs at a
lower molecular weight (67 kDa) as compared with the glycosy-
lated rBCAM (84 kDa). This is indicative of effective deglycosyla-
tion [14]. We spotted CNF1 on nitrocellulose and repeated the
overlay assay as described above with glycosylated recombinant
BCAM and PNGaseF-treated deglycosylated rBCAM. In this
assay CNF1 still interacts with deglycosylated rBCAM (Fig. S4B).
Moreover, treatment of cells with PNGaseF and subsequent
FACS-analysis revealed that the toxin binds with even higher
affinity to the cells (Fig. S4C). This may be due to a higher
Figure 4. CNF1 directly interacts with Lu/BCAM on the cell surface. Suspensions of HeLa cells ((A–C) 16105 cells in 1 ml medium) were
incubated for 20 min at 4uC with 2 mg DyLight488-labeled GST-CNF1 (CNF1DL488) alone or together with increasing amounts of rBCAM protein (A).
Cells were then washed in PBS and subjected to FACS analysis. The experiment was repeated with 2 mg DyLight488-labeled GST-CNF1 (CNF1DL488)
alone or together with increasing amounts of aLu/BCAM antibody (molar ratio CNF:antibody up to 1:50, * p,0.05) (B) or a 50-fold excess of the aLRP
antibody as indicated (C). Data are presented as % fluorescence of control with CNF1DL488 set to 100%. Non- (D) and Lu/BCAM-expressing (E) K562
cells were either left untreated (mock) or were incubated with 2 mg CNF1DL488 for 20 min at 4uC and, following washing with PBS, subjected to FACS
analysis. Results are presented as histogram plots, where single cell events are plotted against cell surface-bound fluorescence (Log FL intensity).
doi:10.1371/journal.ppat.1003884.g004
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accessibility of the protein part of the receptor. The data indicate
that N-glycosylation is not necessary for the interaction of CNF1
with Lu/BCAM. The exclusive precipitation of the high molecular
weight form of the protein from cells may indicate that this is the
surface exposed form of Lu/BCAM.
Defining the CNF1-Lu/BCAM interaction site
Two sites of CNF1 have been described to be necessary for its
interaction with mammalian cells: The N-terminal receptor
binding domain (aa 1–342, [16]) and a small part of CNF1
adjacent to the catalytic domain (aa 683–730, [16]).
To narrow down the region of CNF1, which interacts with Lu/
BCAM, at first we studied direct protein-protein interaction. We
performed dot-blot and surface plasmon resonance (Biacore)
studies with recombinant BCAM and several CNF1 fragments.
Additionally, we used the CNF-family member CNFY, which is
identical in length and shares amino acid identity to CNF1 of 61%
(CNFY) [20]. All proteins were tested for correct folding/activity
in an in vitro Rho shift assay, which indicates deamidation of
recombinant RhoA. As expected, only the N-terminal fragment of
CNF1 (aa 1–342), which does not contain the catalytic domain,
did not catalyze the deamidation of RhoA (Fig. S5). For dot-blots,
we spotted 3 mM solutions of GST-CNFs, GST-CNF fragments
and GST alone, respectively, onto nitrocellulose. After membrane
blockage, recombinant BCAM was added and bound rBCAM was
detected using anti-BCAM antibody. Equal protein load was
analyzed by visualizing the GST part of the spotted proteins with
an anti GST-antibody. As shown in Fig. 5A-top, significantly more
rBCAM bound to CNF1 as compared with CNFY. In contrast,
rBCAM did not interact with GST. The data indicate that CNF1
binds with higher affinity to rBCAM as compared to CNFY. This
is in line with previous competition experiments, which indicate
that CNF1 and CNFY apparently bind to a different receptor
[17,20]. Moreover, the binding site seems to be located in close
proximity to the catalytic domain. The CNF1 fragments 426–
1014, 709–1014 and 720 to 1014 exhibited strong binding to
rBCAM, indicating that amino acids 720 to 1014 of CNF1 are
sufficient for the interaction with this receptor (5A-bottom). In
contrast, the N-terminal part (aa 1–342), which was previously
suggested to be responsible for CNF-receptor interaction, did not
interact with rBCAM.
For quantitative analysis of the protein-protein interaction we
used plasmon resonance spectroscopy (Biacore). For these studies
we used recombinant Lu/BCAM, which contains a C-terminal
human IgG domain for purification (Sino biology). We covalently
coupled an antibody against human IgG to two lanes of a CM5-
biacore chip. For analysis of the rBCAM-CNF1 interaction,
rBCAM as ligand (only to lane 2) and in a second step, CNF
proteins as analyte (both lanes) were guided over the lanes. This
allows for correction of unspecific protein binding to the antibody.
In Fig. 5B bound protein is given as relative units (RU) corrected
for the unspecific binding to lane 1. The data show that the
strongest binding to rBCAM occurs with the full-length toxin
and with the C-terminal part of CNF1, whereas no interaction
with rBCAM could be detected with CNFY or with the N-
terminal part of CNF1 (aa 1–342). The fragment 426–1014 was
weaker in its interaction to Lu/BCAM as compared to the C-
terminal fragments 709–1014 or 720–1014. The difference
between CNF1 (aa 426–1014) and the shorter fragment may
be based on different protein stability or better accessibility of
the receptor binding domain in the shorter fragments which
needs further investigation. The data suggest that the interaction
site of CNF1 with Lu/BCAM is located within amino acids 720 to
1014 and does not occur with the N-terminus (aa 1–342). To
confirm these results, we repeated the FACS experiments
as described above with labeled GST-CNF1 and increasing
amounts of unlabeled CNF1 fragments (molar ratio CNF1:com-
petitor from 1:0 to 1:30, respectively as indicated). Moreover, we
used untagged CNF1 for competition. As expected, the C-terminal
fragments of the toxin (aa 709–1014 and aa 720–1014) were able
to inhibit binding of CNF1 to the cells whereas pre-incubation
with the N-terminus (aa 1–342) had no effect (Fig. 6). In line with
the dot-blot analysis, the fragment 426–1014 was weaker in its
interaction to Lu/BCAM as compared to the C-terminal
fragments.
CNF1 without the N-terminus is not sufficient for the
intoxication of cells
The catalytic part of CNF1 has been localized to amino acids
720 to 1014 [21]. Our data show that the binding site of the toxin
to Lu/BCAM is located adjacent to this part and even overlap.
Therefore, we tested, whether the toxin deleted for the N-terminus
but containing a translocation domain, receptor binding and
catalytic part may be sufficient for intoxication of cells. We
incubated HeLa cells with the CNF1 fragment (aa 343 to 1014),
which contains the catalytic domain, the Lu/BCAM binding site
and additionally the two hydrophobic regions H1 and H2
suggested to mediate insertion into the endosomal membrane
[22]. We lysed the cells and analyzed the modification of RhoA
using the Rho shift assay. Even a high amount of the toxin part
(1,5 mM) added to mammalian cells was not sufficient to intoxicate
the cells (not shown). This indicates that besides the CNF1-Lu/
BCAM interaction, binding to p37LRP is required for the
intoxication of the cells. One explanation could be that the
protein is not released into the cytosol. However, further
experiments are required, to analyze this feature. Our data are
summarized in Fig. 7.
Discussion
Our study sheds new light on the uptake mechanism of the
bacterial toxin CNF1. It is widely accepted that the toxin enters
the cytosol of mammalian cells from endosomes, following
receptor-mediated endocytosis [23]. Inhibition of endosome
acidification with bafilomycin A completely blocks intoxication
of cultured cells [17,24]. Here, we identified Lu/BCAM as a
crucial receptor for the toxin. For precipitation of CNF1-
interacting proteins, we used a method recently employed for
the identification of the alpha-toxin receptor [25]. Following
binding to the surface of living HeLa cells and subsequent lysis, we
isolated the toxin-protein complexes, using magnetic beads. This
method ensures correct folding and orientation of membrane
proteins during toxin binding. Moreover, intracellular proteins
and cytosolic domains of membrane proteins are excluded as
interaction partners. MALDI-TOF analysis of the precipitate
identified Lu/BCAM as interaction partner for CNF1. We verified
CNF1 Lu/BCAM interaction by several methods:
Western-blotting revealed that Lu/BCAM was exclusively co-
precipitated with CNF1 but not with CNFY. Second, dot-blot
analysis with several CNF1 fragments and recombinant BCAM
delineated the site of interaction to the C-terminus (aa 720 to
1014). Finally, we supported our findings with surface plasmon
resonance measurements (Biacore). In this system we were not able
to displace CNF1 from BCAM using several conditions like high
salt buffer (500 mM NaCl, 20 mM Tris/HCl, pH 7.4) basic or
acidic buffer (50 mM NaOH, 10 mM glycine, pH 2.5). Therefore,
it was not possible to calculate the dissociation constant (Kd) of the
rBCAM-CNF interaction.
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Binding to Lu/BCAM occurred with amino acids 720–1014
with comparable affinity as determined for the full-length protein.
Using FACS analysis, we show that this part of the toxin is
sufficient for interaction with the cell surface. Moreover, it is
sensitive for competition with antibodies against Lu/BCAM or
with an excess of recombinant BCAM. In previous studies the
non-integrin laminin receptor precursor 37LRP has been identi-
fied as interaction partner for the N-terminal part of CNF1 in a
yeast two-hybrid screen [8]. This part has been suggested as the
toxins receptor binding domain, because an excess of a
corresponding CNF1 peptide incubated together with full-length
CNF1 blocks intoxication of cells [21]. In line with this, the N-
terminal binding partner 37LRP/67LR seems to be required for
the action of the toxin. It has been shown that 37LRP/67LR is
important for intoxication of mammalian cells and for the opening
of the brain barrier in a mouse model [26,27]. No direct binding
to the cell surface was proven and p37LRP/p67 may have other
functions like transport into the cell.
Surprisingly, we could not find any interaction with Lu/BCAM
and the previously suggested N-terminal receptor binding site.
This suggests that 37LRP/67LR and Lu/BCAM are not
alternative receptors, although they are both laminin-binding
proteins. We found Lu/BCAM to be crucial for binding, because
cells deficient in Lu/BCAM but expressing LRP could not
bind labeled CNF1. This indicates that 37LRP/67LR is not
sufficient for toxin binding. Therefore, we conclude that 37LRP/
67LR and Lu/BCAM are both required for toxin action but
with different functions. We suggest two interaction sites in
CNF1: The N-terminus binding to 37LRP/67LR as postulated
by Kim [8,26] and the C-terminus (probably a region around
amino acids 683–730, [16]) binding with high affinity to Lu/
BCAM. In line with this, two different cell interaction sites of
Figure 5. Direct rBCAM-CNF interaction. A) For dot-blots 5 ml of 3 mM solutions of GST-CNFs, GST-CNF fragments and GST alone, respectively,
were spotted onto a nitrocellulose membrane. The membrane was blocked with skimmed milk and recombinant BCAM (6 mM) was added for 1 h at
room temperature. Following washing bound rBCAM was detected with an anti-Lu/BCAM antibody. Equal protein load was analyzed by visualizing
the GST part of the spotted proteins with an anti GST-antibody. B) Biacore protein-protein interaction studies: An antibody against human IgG
(Millipore) was coupled to two lanes of a CM5-biacore chip. As ligand recombinant BCAM containing a C-terminal human IgG domain (Sino biologics)
was exclusively guided over lane 2. In a second step, GST-CNF proteins as analyte were guided over both lanes. Bound protein is given as relative
units (RU) corrected for the unspecific binding to lane 1 as average plus standard deviation of three independent experiments.
doi:10.1371/journal.ppat.1003884.g005
Identification of CNF1 Receptor
PLOS Pathogens | www.plospathogens.org 8 January 2014 | Volume 10 | Issue 1 | e1003884
CNF1 have been identified by McNichol and coworkers, which
both are necessary for efficient intoxication of cells [16]. Our
data show that Lu/BCAM is required for toxin binding. However,
it is not sufficient for intoxication of mammalian cells, since
CNF1 deleted for the N-terminal 342 amino acids can bind to
cells but is not able to intoxicate them. What is the role of the N-
terminus and its interaction with 37LRP/67LR? We observed
that the N-terminal part of CNF1 forms SDS stable tetramers,
Figure 6. CNF1 binds to the cell surface via a C-terminal peptide. Suspensions of HeLa cells (16105 cells in 1 ml medium) were incubated for
20 min at 4uC with 2 mg DyLight488-labeled GST-CNF1 (CNF1DL488) alone, or together with increasing amounts (up to 30 fold) of untagged non-
labeled CNF1 and the non-labeled fragments GST-CNF1-(426–1014), GST-CNF1-(720–1014), GST-CNF1-(709–1014) and GST-CNF1-(1–343),
respectively. Following washing with PBS, cells were subjected to FACS analysis. Results are presented as mean of cell surface-bound fluorescence
(% of control) of three independent experiments+standard deviation.
doi:10.1371/journal.ppat.1003884.g006
Figure 7. Summary of the CNF1 domain structure. CNF1 consists of 1014 amino acids. We found amino acids 1–342 responsible for interaction
with the laminin receptor precursor (37LRP). Binding to Lu/BCAM occurs with amino acids 720 to 1014. Data from the literature suggest amino acids
683–730 to mediate binding to mammalian cells [16] indicating this part to be responsible for BCAM binding (white box, RBD). The C-domain
represents the catalytic part of the toxin. The two hydrophobic helices (H1 and H2) are crucial for insertion into the endosomal membrane.
doi:10.1371/journal.ppat.1003884.g007
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although only a small fraction of the purified protein was found
in the oligomer-band (data not shown). Further studies are
required to analyze a possible oligomerization of CNF1. We
speculate that 37LRP/67LR may bind to the pre-formed oligomer
and may play a crucial role for the uptake of CNF1 into the
cytosol. Initial binding of the toxin to the cell surface requires Lu/
BCAM. It remains to be analyzed, whether interaction of an
oligomer is required for pore-formation in the endosomal
membrane and/or for transport of the catalytic domain into the
cytosol.
Taken together, we present a novel model of the action of
CNF1, which is outlined in Fig. 7. We suggest that CNF1 binds to
the surface of mammalian cells with its receptor binding domain
located adjacent to the catalytic domain. The crystal structure of
the catalytic domain (aa 720–1014) reveals an additional helix (aa
720 to 734) sticking out of the otherwise globular structure (735 to
1014). This part does not directly contribute to the catalytic core
domain of the toxin [28] but may connect the receptor binding
domain of CNF1 with the catalytic domain or even is part of the
Lu/BCAM interaction site. Further studies are required to analyze
this important feature.
We have shown recently that cleavage of CNF1 enhances its
biologic activity and that this cleavage does not occur in the
cytosol but either on the cell surface or within endosomes [29].
Two surface binding sites (one at the N-terminus and the other
near the C-terminus) would allow toxin cleavage on the
membrane/vesicle surface without losing the interaction of
separated toxin parts. This allows subsequent pore formation
and translocation. Thus, while some toxins (e.g., diphtheria toxin)
are functionally connected by SS-bridges, CNF might use two cell
surface binding sites for efficient up-take.
Methods
Cell culture
HeLa and Hek293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum, 1% nonessential amino acids, penicillin (4 mM), and
streptomycin (4 mM).
K562 wt and K562 Lu/BCAM (provided by Anne Filipe,
INSERM Paris) were grown in RPMI (RPMI-1640) containing
10% fetal calf serum, penicillin (4 mM) and streptomycin (4 mM).
K562 cells expressing Lu/BCAM were grown in medium
containing 1 mM Geniticin. T47D cells were cultured in DMEM
supplemented with 10% fetal calf serum, 1% nonessential amino
acids, penicillin (4 mM), and streptomycin (4 mM) and 80 iU/l
insulin.
All cell lines were cultivated in a humidified atmosphere
containing 5% CO2 at 37uC.
For competition experiments cells were grown to subconfluency
and treated with appropriate amounts of toxin for 1 to 16 h, as
indicated. For competition assays cells were pre-incubated with
antibodies against Lu/BCAM, or the toxins were pre-treated with
recombinant BCAM (Sinobiologics) prior to intoxication as
indicated.
Cell lysates were generated as follows: Cells were washed twice
with phosphate buffered saline (PBS) and lysed with GST-Fish
buffer (10% glycerol, 50 mM Tris/HCl, pH 7.4, 100 mM NaCl,
1% NP-40, 2 mMMgCl2 and 1 mM PMSF). Lysates were cleared
by centrifugation (20 min, 21,000 g, 4uC). To separate cytosolic
and membrane fractions, lysates were centrifuged (1 h, 100,000 g,
4uC). Membrane pellets were dissolved in hot sample buffer
(100 mM Tris (pH 6.8), 10% sodium dodecyl sulfate (SDS), 10%
glycerol, 100 mM dithiotreitol (DTT)).
Sample preparation, LC-MS/MS and data analysis
In-gel digests were performed as described in standard
protocols. Briefly, the excised gel bands were destained with
30% ACN, shrunk with 100% ACN, and dried in a Vacuum
Concentrator (Concentrator 5301, Eppendorf, Hamburg, Ger-
many). Digests with trypsin were performed overnight at 37uC in
0.1 M NH4HCO3 (pH 8). About 0.1 mg of protease was used for
one gel band. Peptides were extracted from the gel slices with 5%
formic acid.
All LC-MS/MS analyses were performed on an ion trap mass
spectrometer (Agilent 6340, Agilent Technologies) coupled to an
1200 Agilent nanoflow system via a HPLC-Chip cube ESI
interface. Peptides were separated on a HPLC-Chip with an
analytical column of 75 mm i.d. and 150 mm length and a 40-nL
trap column both packed with Zorbax 300SB C-18 (5 mm particle
size). Peptides were eluted with a linear acetonitrile gradient with
1%/min at a flow rate of 300 nL/min (starting with 3%
acetonitrile).
MS/MS analyses were performed using data-dependent acqui-
sition mode. After a MS scan (standard enhanced mode), a
maximum of three peptides were selected for MS/MS (CID,
standard enhanced mode). The automated gain control was set to
350000. The maximum accumulation time was set to 300 ms.
Mascot Distiller 2.1 (Matrix Science, UK) was used for raw data
processing and for generating peak lists, essentially with standard
settings for the Agilent ion trap. Mascot Server 2.2 (Matrix
Science, UK) was used for database searching with the following
parameters: peptide mass tolerance: 1.1 Da, MS/MS mass
tolerance: 0.3 Da, 13C: 1, enzyme: trypsin with max. 2 missed
cleavage, variable modifications: GlnRpyroGlu (N-term. Q),
oxidation (M) and carbamidomethyl (C). The SwissProt database
was used for database searching. Scaffold 4.0.4 (Proteome
Software, USA) was used for statistical analysis and filtering of
the search results (protein threshold: 99%, peptide threshold: 80%,
minimum number of peptides: 2).
Purification of 37LRP/67LR
The 67LR was purified from T47D human breast carcinoma
cells (obtained from Marc Hirschfeld, Albert-Ludwigs-Universita¨t;
Frauenklinik).
After rotational incubation these cells shed the receptor into the
medium.
Cells were grown up to 70–75% confluency, washed with
calcium-free PBS and harvested by trypsination for 5 minutes with
TE (Trypsin-EDTA).
The cells were centrifuged at 800 g for 10 minutes. Approxi-
mately 26107 cells were suspended in 1 ml ice-cold PBS and
incubated for 4 h at 37uC under rotation. After removal of the
cells by centrifugation at 16000 g for 15 min the shed receptor was
precipitated from the supernatant with acetone or frozen at 2
80uC.
SDS-PAGE and western-blotting
Cell lysates were separated by 12.5% SDS-PAGE (for RhoA-
shift assay 15% urea-SDS-PAGE) and transferred onto a
polyvinylidene difluoride membrane. Membranes were either
blocked with skimmed milk (5%) or bovine serum albumin (BSA,
3%) for 1 h at room temperature. Proteins were detected using
anti-CNF1 monoclonal antibody (1:3000; Santa Cruz), anti-RhoA
monoclonal antibody (1:500; Santa Cruz), anti-Lu/BCAM
(1:2500; Abcam; 1:1000; Santa Cruz) or anti-LRP (1:1000, Santa
Cruz) and a respective horseradish peroxidase-coupled second
antibody. Detection occurred by enhanced chemiluminescence.
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Immunoprecipitation
Hek293 and HeLa cells (2–3 subconfluent 15 cm dishes)
were incubated with GST-CNF1-GST, GST-CNFY-GST or
GST (500 ng/ml, respectively) for 20 min at 4uC. Cells were
harvested and lysed and the IP was conducted using anti-GST
magnetic beads according to the manufacturers manual (Miltenyi
Biotech).
Dot-blot
CNF proteins in given concentrations were spotted onto a
nitrocellulose membrane at 4uC. After drying, membranes were
incubated with 5 nM recombinant BCAM in TBST, 30 min at
4uC and blocked in 5% milk for 1 h at room temperature. The
membranes were washed 3 times with TBST (Tris buffered saline;
0.05% Tween-20). Binding of rBCAM was detected using anti-
Lu/BCAM antibodies (1:2500; Abcam). GST served as control
and was detected with anti-GST antibodies (1:500; Santa Cruz).
Detection occurred by enhanced chemiluminescence with horse-
radish peroxidase-coupled second antibodies.
Surface plasmon resonance (Biacore)
An antibody against human IgG (Santa Cruz, 20 mg/mL) was
covalently coupled to two lanes of a CM5-biacore chip with
400 mM N-ethyl-N-dimethylaminopropyl-carbodiimide (EDC)
and 100 mM N-hydroxy-succinimide (NHS). The lanes were
saturated with 1M ethanolamine. As ligand recombinant BCAM
containing a C-terminal human IgG domain (0.2 mM) was
exclusively guided over lane 2. In a second step, CNF proteins
as analyte (1 mM) were guided over both lanes. Bound protein was
determined as relative units (RU) corrected for the unspecific
binding to lane 1. Regeneration occurred with 10 mM glycine/
HCl, pH 2.5.
FACS
Cells were detached from culture dishes by incubation with
10 mM EDTA/PBS. The cell suspension was washed twice with
PBS and kept on ice. 250,000 cells were incubated 20 min at 4uC
with different concentrations of labeled toxins, and fluorescence
was measured with a fluorescence-activated cell sorter (FACS)
using the BD FACSCalibur platform. Cell surface-bound fluores-
cence was detected with an argon-ion laser (488 nm) and the 530-
nm-band-pass filter (FITC). Toxins were labeled according to the
manufacturer’s manual (DyLight 488 carboxylic acid succinimidyl
ester (Invitrogen).
For competition assays cells were either pre-incubated with anti-
Lu/BCAM (Santa Cruz) or the toxins were pre-incubated with
recombinant BCAM (Sinobiologics).
Immunostaining
Cells were washed with phosphate buffered saline (PBS) and
prefixed with ice cold methanol supplemented with 1 mM EGTA.
After 10 min cells were transferred to 4% formaldehyde in PBS,
washed, permeabilized with 0.15% Triton X-100 in PBS for
10 min and blocked by 1% BSA in PBS for 30 min. Incubation
with the primary antibody (anti-EEA1 1:200, Santa Cruz) (anti-
Lu/BCAM 1:150, Santa Cruz) was overnight at 4uC in PBS. Cells
were washed with PBS and incubated with the suitable secondary
antibody in PBS for 1 h at room temperature. Cells were washed,
dried and embedded with Mowiol supplemented with DABCO
(Sigma, St. Louis, MO, USA). Cells were analyzed with an
inverted Axiovert 200 M microscope (Carl Zeiss GmbH, Jena,
Germany), driven by Metamorph imaging software (Universal
Imaging, Downingtown, PA, USA), with a Yokogawa CSU-X1
spinning disc confocal head (Tokyo, Japan) with emission filter
wheel, with a Coolsnap HQ II digital camera and with 488 nm
and 561 nm laser lines. Images were processed with Metamorph
software.
Supporting Information
Figure S1 Maldi-TOF analysis of co-precipitated proteins.
Hek293 cells were incubated with GST-CNF1-GST, GST-
CNFY-GST or GST for 20 min at 4uC. Cells were harvested
and lysed and the IP was conducted using anti-GST magnetic
beads according to the manufacturers manual (Miltenyi Biotech).
Proteins were separated by SDS-PAGE and analyzed by MALDI-
TOF analysis.
(TIFF)
Figure S2 Presence of 37LRP/67LR and Lu/BCAM in
HEK293, HeLa, K562 and K562-LU/BCAM cells. Cell lysates
were separated by SDS-PAGE and blotted onto a PVDF
membrane. 37LRP/67LR and LU/BCAM were detected with
specific antibodies.
(TIFF)
Figure S3 FACS-based analysis of CNF1 binding to HeLa cells.
Suspensions of HeLa cells (16105 cells in 1 ml medium) were
incubated for 20 min at 4uC with indicated concentrations of
DyLight488-labeled GST-CNF1 (CNF1DL488), washed with PBS,
and subjected to FACS analysis. Left: Results are presented as
histogram plots, where single cell events are plotted against cell
surface-bound fluorescence (Log FL intensity). Right: Data from 3
independent experiments (3.5 to 35 nM CNF1DL488) were
quantified and are presented as arbitrary units (AU)+standard
deviation.
(TIFF)
Figure S4 Role of Lu/BCAM glycosylation. Recombinant
BCAM was treated with PNGaseF and analyzed deglycosylation
by SDS-PAGE. De-glycosylated rBCAM runs faster according to
its lower molecular weight (67 kDa) as compared with the
glycosylated BCAM (84 kDa) (A). GST-CNF1, GST-CNFY and
GST were spotted onto a nitrocellulose membrane. An overlay
assay with glycosylated recombinant BCAM and PNGaseF-
treated, de-glycosylated rBCAM was performed. Following
washing bound rBCAM was detected with an anti-Lu/BCAM
antibody. Equal protein load was analyzed by visualizing the GST
part of the spotted proteins with an anti GST-antibody (B). Facs-
analysis revealed that the toxin binds with higher affinity to the
cells (C): Suspensions of PNGase F-treated (white, dashed lined
peaks) or untreated (dark grey peaks) HEK293 cells (16105 cells
in 1 ml medium) were incubated for 20 min at 4uC with 2 mg
of DyLight488-labeled GST-CNF1 (CNF1DL488) or without
protein (mock), washed with PBS, and subjected to FACS analysis.
Results are presented as histogram plots, where single cell events
are plotted against cell surface-bound fluorescence (Log FL
intensity).
(TIFF)
Figure S5 Recombinant CNF1 fragments are folded correctly.
Recombinant RhoA (5 mM) was incubated with GST-CNF1 and
GST-CNF1 fragments (each 1 mM), respectively as indicated in a
buffer, containing 50 mM TRIS-HCl, pH 7.5, 5 mM MgCl2,
1 mM EDTA, and 1 mM DTT for 4 h at 37uC. Proteins were
loaded onto 12.5% SDS-gel containing 1 M urea. The samples
were analyzed for the typical shift of deamidated RhoA to higher
molecular weight.
(TIFF)
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